Home Featured Page 68

Featured

Latest

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin Approval

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical, and Increasingly Coordinated

Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future

“If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics

Q4 2025: Oregon Psilocybin Services Update

Pα+ Psychedelic Bulletin #155: MAPS Invests in Numinus, Hopes to Offer...

Sacred Mycology Summit: A Three Day Online Educational Gathering

Magic Mushroom Industry Leaders: Top Cultivation Companies

The Psychedelic Drug Development Pipeline: Bullseye Chart Year-End 2023

PT484 – Seeing Through the Smoke: The Importance of Telling the...

PT483 – Traumatic Brain Injuries, the Gut Microbiome, and the Potential...

A Discussion with Ernesto Londoño, Author of “Trippy: The Peril and...

Caught in the Act: A Chemist’s Battle Against Felony Drug Charges

Interview: Compass Pathways CEO Kabir Nath Discusses Commercialisation, ‘Psychological Support’ and...

PT482 – Behind the Scenes: A Conversation on Psychedelic Business, Media,...

EDITOR PICKS

Field Notes #1: Psychiatrists, Regulators, Ibogaine, and the Race for Psilocybin...

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

Bit Yaden on Preparing the Next Generation of Psychiatrists for a...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.